This invention provides compounds defined by Formula I or a pharmaceutically acceptable salt thereof,wherein R1, Q, Y2, Y3, Y4, U5, U6, U8, and R2 are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier,
diluent, or
excipient. The invention also provides methods of inhibiting an MMP-13
enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a
disease mediated by an MMP-13
enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as
heart disease,
multiple sclerosis, osteo- and
rheumatoid arthritis,
arthritis other than osteo- or
rheumatoid arthritis, cardiac insufficiency,
inflammatory bowel disease,
heart failure, age-related
macular degeneration, chronic obstructive
pulmonary disease,
asthma, periodontal diseases,
psoriasis, atherosclerosis, and
osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically
active component as described in the specification.